Mark Carlton

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA.

Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC.

Accenture LLC operates as a global management consulting, technology services and outsourcing company. The company is headquartered in Reston, VA.

University of Iowa Hospitals and Clinics recognized as one of the best hospitals in the United States is Iowa's only comprehensive academic medical center. A 680-bed comprehensive academic medical center and regional referral center, UI Hospitals and Clinics is committed to providing patient-focused care available to every person, around the clock in an environment devoted to innovative care, excellent service, and exceptional outcomes. More than 760 staff physicians and dentists; 480 resident physicians and dentists; 180 fellow physicians; 1,565 nurses; and 4,640 other professional and support staff provide specialized care.

Foundry Innovation & Research 1 Ltd. develops novel therapeutic devices. It has evolved into one of the leading clusters for medical devices globally. The company was headquartered in Dublin, Ireland.

Relievant Medsystems, Inc. develops treatment and technologies for chronic back pain. Its Intracept System solution is a minimally invasive procedure that uses radiofrequency energy delivered into the vertebral body of the spine to ablate the basivertebral nerve. Relievant Medsystems was founded by James C. Peacock, Jeffrey Charles Lotz, and Rex Peters in 2004 and is headquartered in Redwood City, CA.

Evalve, Inc. designs, develops, manufactures and markets devices. It developed a proprietary system which enables percutaneous repair of cardiac valves. The firm's products reduces the risks, trauma, and costs associated with current open, arrested heart surgical options. The company was founded on June 9, 1999 and is headquartered in Menlo Park, CA.

LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California.

Alx Oncology Ltd. operates as biotechnology company developing immuno-oncology therapies for cancer. The company was founded by Kipp Weiskopf and Jaume Pons in 2015 and is headquartered in Ireland, Dublin.

Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Tarsus Medical, Inc. develops novel solutions for unsolved problems within the field of podiatry. The company was founded in 2009 and is headquartered in Mountain View, CA

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

The Structural Genomics Consortium is a non-profit organization that accelerates research by sharing all of its research output with the scientific community without any restrictions. The private company is based in Headington, UK. The British company has created an open collaborative network of scientists in hundreds of universities worldwide and nine pharmaceutical companies. The company was founded by Pär Nordlund.

Part of Takeda Pharmaceutical Co., Ltd., Takeda Cambridge Ltd. is a company that develops and manufactures pharmaceutical products. The company is based in Cambridge, UK and was founded in 1998.

Biofocus, Inc. operates as a clinical biotechnology company. The company is headquartered in the United Kingdom.

Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016.

Split Rock Partners LLC (Split Rock Partners) is a venture capital firm founded by Jim Simons, Michael Gorman, David Stassen. The firm is headquartered in Eden Prairie, Minnesota.

Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California.

Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA.

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.

Part of SV Health Investors LLP, Dementia Discovery Fund is a venture capital fund. The company is based in London, UK. Founded in 2015, Dementia Discovery Fund operates as a venture capital fund.

Generian Pharmaceuticals, Inc. provides pharmaceutical services. The company is headquartered in Pittsburgh, PA.